The relevant information included in this section is exactly as published on the website of the National Securities Market Commission (CNMV)

Filter results
Date Title Content PDF
29/04/2021 On business and financial situation The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States.    
12/04/2021 On business and financial situation The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine.
6/04/2021 Liquidity contracts and specialists Liquidity contract: transactions conducted in the first quarter of 2021
2/03/2021 On business and financial situation The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States 
2/03/2021 On business and financial situation The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States 
24/02/2021 Annual Corporate Governance Report ROVI releases the 2020 Annual Corporate Governance Report
24/02/2021 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2020 annual report regarding remuneration of the members of the Board of Directors 
24/02/2021 On business and financial situation The company releases the press release related to 2020 financial results
24/02/2021 On business and financial situation ROVI releases the 2020 Results presentation
24/02/2021 About corporate governance The Company informs about the agreements adopted by the Board of Directors 

Pages